New molecular inhibitors hit difficult cancer target
Tuesday, February 5, 2013 - 19:30
in Health & Medicine
Early laboratory tests are the first to successfully use an experimental molecular therapy to block a hard-to-target part of a protein complex linked to several types of invasive cancer. Scientists report the rational design of a small-molecule inhibitor they call Y16. In laboratory tests, the inhibitor helped stop the spread of cultured human breast cancer cells, especially when it was used with another compound known as Rhosin/G04.